The proposed acquisition would combine the two largest providers of outsourced hydrophilic coatings, Surmodics and Biocoat, which is majority owned by GTCR, giving the merged company control of over 50% of the market, according to a March 6 news release from the agency.
The coatings play a vital role in medical devices such as catheters and guidewires.
The FTC warned that eliminating competition between Surmodics and Biocoat would lead to high prices, reduced innovation and lower-quality products, ultimately harming medical devices and patients.
Becker’s reached out to GTCR BC Holdings and Surmodics for comment and will update this story if more information becomes available.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
